![](/img/cover-not-exists.png)
Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction the CSL112–2001 trial
Gibson, C. Michael, Kerneis, Mathieu, Yee, Megan K., Daaboul, Yazan, Korjian, Serge, Mehr, Ali Poyan, Tricoci, Pierluigi, Alexander, John H., Kastelein, John J.P., Mehran, Roxana, Bode, Christoph, LewLanguage:
english
Journal:
American Heart Journal
DOI:
10.1016/j.ahj.2018.11.008
Date:
November, 2018
File:
PDF, 580 KB
english, 2018